Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLSD NASDAQ:DYAI NASDAQ:KPRX NASDAQ:MDCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSDClearside Biomedical$0.38-7.8%$0.72$0.29▼$1.65$29.85M2.0913.04 million shs814,430 shsDYAIDyadic International$1.01-5.2%$0.99$0.91▼$2.20$30.24M0.89204,236 shs145,597 shsKPRXKiora Pharmaceuticals$2.54-2.3%$3.01$2.51▼$4.77$7.73M-0.6466,840 shs63,638 shsMDCXMedicus Pharma$2.57+4.5%$3.05$1.80▼$8.94$34.88MN/A535,866 shs169,074 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSDClearside Biomedical0.00%-22.75%-53.27%-55.84%-66.31%DYAIDyadic International0.00%-8.64%+7.95%-16.19%-28.72%KPRXKiora Pharmaceuticals0.00%-15.05%-11.31%-23.49%-45.14%MDCXMedicus Pharma0.00%-12.29%-23.96%-41.72%+256,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLSDClearside Biomedical2.3913 of 5 stars4.15.00.00.00.60.00.0DYAIDyadic International2.0731 of 5 stars3.54.00.00.00.61.70.0KPRXKiora Pharmaceuticals3.1163 of 5 stars3.55.00.00.00.01.70.6MDCXMedicus Pharma2.4642 of 5 stars3.80.00.00.03.31.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSDClearside Biomedical 2.17Hold$4.20993.47% UpsideDYAIDyadic International 3.00Buy$6.00497.01% UpsideKPRXKiora Pharmaceuticals 3.00Buy$10.00293.70% UpsideMDCXMedicus Pharma 3.50Strong Buy$23.50814.40% UpsideCurrent Analyst Ratings BreakdownLatest KPRX, CLSD, DYAI, and MDCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/18/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$5.007/18/2025CLSDClearside BiomedicalChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral7/18/2025CLSDClearside BiomedicalStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$2.007/17/2025CLSDClearside BiomedicalJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/17/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold$3.007/9/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.007/1/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.006/23/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.006/9/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.005/29/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.005/23/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $5.00(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSDClearside Biomedical$1.66M17.98N/AN/A($0.51) per share-0.75DYAIDyadic International$3.49M8.66N/AN/A$0.08 per share12.56KPRXKiora Pharmaceuticals$16.02M0.48$1.24 per share2.05$8.58 per share0.30MDCXMedicus PharmaN/AN/AN/AN/A$0.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSDClearside Biomedical-$34.35M-$0.41N/AN/AN/A-818.57%N/A-114.23%8/11/2025 (Estimated)DYAIDyadic International-$5.81M-$0.20N/AN/AN/A-163.94%-233.69%-59.37%8/12/2025 (Estimated)KPRXKiora Pharmaceuticals$3.60M-$2.90N/AN/AN/AN/A-42.82%-32.18%8/8/2025 (Estimated)MDCXMedicus Pharma-$11.16M-$1.16N/AN/AN/AN/A-380.03%-224.22%8/7/2025 (Estimated)Latest KPRX, CLSD, DYAI, and MDCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025DYAIDyadic International-$0.06N/AN/AN/A$0.60 millionN/A8/11/2025Q2 2025CLSDClearside Biomedical-$0.12N/AN/AN/A$0.50 millionN/A8/8/2025Q2 2025KPRXKiora Pharmaceuticals-$0.58N/AN/AN/A$0.75 millionN/A8/7/2025N/AMDCXMedicus Pharma-$0.39N/AN/AN/AN/AN/A5/14/2025Q1 2025CLSDClearside Biomedical-$0.12-$0.11+$0.01-$0.11$0.20 million$2.33 million5/14/2025Q1 2025DYAIDyadic InternationalN/A-$0.07N/A-$0.07N/A$0.39 million5/12/2025Q1 2025MDCXMedicus Pharma-$0.23-$0.42-$0.19-$0.42N/AN/A5/9/2025Q1 2025KPRXKiora Pharmaceuticals-$0.77-$0.52+$0.25-$0.52$0.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLSDClearside BiomedicalN/AN/AN/AN/AN/ADYAIDyadic InternationalN/AN/AN/AN/AN/AKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSDClearside BiomedicalN/A3.193.19DYAIDyadic International5.403.983.98KPRXKiora PharmaceuticalsN/A5.145.14MDCXMedicus PharmaN/A1.531.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSDClearside Biomedical18.75%DYAIDyadic International27.95%KPRXKiora Pharmaceuticals76.97%MDCXMedicus PharmaN/AInsider OwnershipCompanyInsider OwnershipCLSDClearside Biomedical6.20%DYAIDyadic International29.50%KPRXKiora Pharmaceuticals0.05%MDCXMedicus Pharma11.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLSDClearside Biomedical3077.71 million72.89 millionOptionableDYAIDyadic International730.09 million21.21 millionOptionableKPRXKiora Pharmaceuticals103.04 million3.04 millionNot OptionableMDCXMedicus PharmaN/A13.57 million12.05 millionN/AKPRX, CLSD, DYAI, and MDCX HeadlinesRecent News About These CompaniesMedicus Pharma Appoints Deloitte for Licensing DealJuly 30, 2025 | tipranks.comMedicus Pharma Ltd. Strengthens Board with New AppointmentsJuly 23, 2025 | tipranks.comMedicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of ShareholdersJuly 23, 2025 | newsfilecorp.comNMedicus Pharma Ltd. Announces Submission of Type C Meeting Request to ...July 23, 2025 | finanznachrichten.deMedicus Pharma Ltd.: Medicus Pharma Ltd Announces a Definitive ...July 23, 2025 | finanznachrichten.deMedicus Pharma Ltd. Expands Clinical Trials and Announces Strategic AcquisitionJuly 21, 2025 | tipranks.comMedicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025July 21, 2025 | newsfilecorp.comNMedicus Pharma Ltd. (NASDAQ:MDCX): Novel Pipeline Presents Unique Opportunity To Capitalize On Rare Disease Market Worth Over $15 BillionJuly 16, 2025 | theglobeandmail.comMEDICUS PHARMA LTD - FinanzNachrichten.deJuly 16, 2025 | finanznachrichten.deMedicus Pharma Enters Warrant Inducement AgreementJuly 14, 2025 | tipranks.comMedicus Pharma submits Type C meeting request to FDA to advance skin cancer treatmentJuly 8, 2025 | proactiveinvestors.comMedicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)July 8, 2025 | newsfilecorp.comNMedicus Pharma expands pipeline with Antev acquisition - ICYMIJuly 5, 2025 | proactiveinvestors.comMedicus Pharma: High-Risk But Higher Reward For Their Potential Breakthrough Skin Cancer TreatmentJuly 4, 2025 | seekingalpha.comMedicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK - Seeking AlphaJuly 2, 2025 | seekingalpha.comMedicus to acquire UK biotech Antev in share deal worth up to $65mJune 30, 2025 | proactiveinvestors.comMedicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UKJune 30, 2025 | newsfilecorp.comNMedicus Pharma appoints Andrew Smith as chief operating officerJune 24, 2025 | uk.investing.comMedicus Pharma appoints COO; updates on SKNJCT-003June 24, 2025 | thepharmaletter.comTMedicus Pharma names Andrew Smith as COO, advances BCC and prostate drug studiesJune 23, 2025 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKPRX, CLSD, DYAI, and MDCX Company DescriptionsClearside Biomedical NASDAQ:CLSD$0.38 -0.03 (-7.80%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.39 +0.01 (+2.58%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Dyadic International NASDAQ:DYAI$1.00 -0.06 (-5.19%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.02 +0.02 (+1.49%) As of 08/1/2025 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Kiora Pharmaceuticals NASDAQ:KPRX$2.54 -0.06 (-2.31%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.49 -0.05 (-1.97%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.Medicus Pharma NASDAQ:MDCX$2.57 +0.11 (+4.47%) As of 08/1/2025 04:00 PM EasternMedicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
